Finance Watch: PTC Raises $1bn In Evrysdi Royalty Deal Weeks After Latest Layoffs

Abivax Launches 19th US Biopharma IPO Of 2023

Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.

Finance Watch Public Company
• Source: Alamy

PTC Therapeutics, Inc. will receive $1bn as it expands a deal it did with Royalty Pharma plc in 2020 around royalties from the PTC/Roche Holding AG-partnered spinal muscular atrophy drug Evrysdi (risdiplam). The new influx of cash was revealed on 19 October, less than a month after the company announced a 25% workforce reduction – its second round of job cuts in 2023.

South Plainfield, NJ-based PTC initially received $650m from Royalty Pharma three years ago when it agreed to sell 43% of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.